FAM245A: A Potential Drug Target and Biomarker (G728218)

Target Name: FAM245A

NCBI ID: G728218

FAM245A

Other Name(s): Family with sequence similarity 245 member A | family with sequence similarity 245 member A | LINC00864

FAM245A: A Potential Drug Target and Biomarker

FAM245A is a protein that belongs to the family of RNA-protein interactions (RISC) proteins, which are known for their ability to interact with specific RNA molecules. FAM245A is characterized by a sequence similarity of 245 nucleotides between its amino acid sequence and the sequence of the protein encoded by the HOXA9 gene. This sequence similarity has led to the hypothesis that FAM245A may be a drug target or biomarker.

The HOXA9 gene is a key regulator of the development and maintenance of tissues, including the uterus and the breast. It is a transcription factor that is involved in the regulation of gene expression, and is expressed in a variety of tissues, including the uterine epithelial cells, the endometrial cells, and the breast epithelial cells. HOXA9 has been implicated in the development and progression of various breast cancers, including estrogen-sensitive and estrogen-resistant tumors.

FAM245A is a potential drug target for HOXA9 because it is highly conserved in its sequence compared to the human HOXA9 gene. The sequence similarity between FAM245A and HOXA9 has led to the prediction that FAM245A may interact with HOXA9 and regulate its activity. This interaction between FAM245A and HOXA9 may be important for the regulation of cell growth, differentiation, and cancer progression.

FAM245A has also been suggested as a potential biomarker for the diagnosis and prognosis of breast cancer. The expression of FAM245A has been shown to be elevated in a variety of breast cancer tissues, including those from estrogen-sensitive and estrogen-resistant tumors. This suggests that FAM245A may be a useful biomarker for the diagnosis and prognosis of breast cancer, particularly in cases where the disease is sensitive to hormone therapy.

In addition to its potential drug and biomarker applications, FAM245A is also of interest as a potential therapeutic target for breast cancer. The regulation of FAM245A by HOXA9 may be a target for small molecules that can inhibit HOXA9 activity and reduce the growth and spread of breast cancer cells. This may be a promising area of research for the development of new treatments for breast cancer.

In conclusion, FAM245A is a protein that has significant potential as a drug target and biomarker for breast cancer. Its high degree of sequence similarity with the HOXA9 gene and its expression in breast cancer tissues make it a promising candidate for manipulation with small molecules. Further research is needed to determine the full extent of FAM245A's involvement in the regulation of HOXA9 activity and its potential as a drug or biomarker for breast cancer.

Protein Name: Family With Sequence Similarity 245 Member A

The "FAM245A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM245A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets